Aeolus Pharmaceuticals Announces NIH Counteract Grant Award to Develop AEOL 10150 as a Treatment Against Nerve Agent Exposure

Aeolus Pharmaceuticals, Inc.

, today announced that NIH CounterACT has awarded a $735,951 contract to Manisha Patel, PhD at the University of Colorado Anschutz Medical Campus to develop AEOL 10150 as a medical countermeasure against nerve agents, titled "Evaluation of Neuroprotective Effects of AEOL 10150 against Chemical Threat Agents."